BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 15374947)

  • 1. alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression.
    Swallow CJ; Partridge EA; Macmillan JC; Tajirian T; DiGuglielmo GM; Hay K; Szweras M; Jahnen-Dechent W; Wrana JL; Redston M; Gallinger S; Dennis JW
    Cancer Res; 2004 Sep; 64(18):6402-9. PubMed ID: 15374947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of BMP-induced ectopic bone formation by Ahsg.
    Rittenberg B; Partridge E; Baker G; Clokie C; Zohar R; Dennis JW; Tenenbaum HC
    J Orthop Res; 2005 May; 23(3):653-62. PubMed ID: 15885488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth inhibition due to complementation of transforming growth factor-beta receptor type II-defect by human chromosome 3 transfer in human colorectal carcinoma cells.
    Miyafuji Y; Zhong X; Uchida I; Koi M; Hemmi H
    J Cell Physiol; 2001 Jun; 187(3):356-64. PubMed ID: 11319759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis.
    Go C; Li P; Wang XJ
    Cancer Res; 1999 Jun; 59(12):2861-8. PubMed ID: 10383147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
    Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
    Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
    Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer.
    Sterner-Kock A; Thorey IS; Koli K; Wempe F; Otte J; Bangsow T; Kuhlmeier K; Kirchner T; Jin S; Keski-Oja J; von Melchner H
    Genes Dev; 2002 Sep; 16(17):2264-73. PubMed ID: 12208849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer.
    Matsuzaki K; Kitano C; Murata M; Sekimoto G; Yoshida K; Uemura Y; Seki T; Taketani S; Fujisawa J; Okazaki K
    Cancer Res; 2009 Jul; 69(13):5321-30. PubMed ID: 19531654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.
    Kalo E; Buganim Y; Shapira KE; Besserglick H; Goldfinger N; Weisz L; Stambolsky P; Henis YI; Rotter V
    Mol Cell Biol; 2007 Dec; 27(23):8228-42. PubMed ID: 17875924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
    Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
    Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition.
    Yang J; Dai C; Liu Y
    J Am Soc Nephrol; 2005 Jan; 16(1):68-78. PubMed ID: 15537870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells.
    Saito RA; Watabe T; Horiguchi K; Kohyama T; Saitoh M; Nagase T; Miyazono K
    Cancer Res; 2009 Apr; 69(7):2783-91. PubMed ID: 19293183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone.
    Mourskaia AA; Dong Z; Ng S; Banville M; Zwaagstra JC; O'Connor-McCourt MD; Siegel PM
    Oncogene; 2009 Feb; 28(7):1005-15. PubMed ID: 19079339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta.
    Tojo M; Hamashima Y; Hanyu A; Kajimoto T; Saitoh M; Miyazono K; Node M; Imamura T
    Cancer Sci; 2005 Nov; 96(11):791-800. PubMed ID: 16271073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic function of a novel WD-domain protein, STRAP, in human carcinogenesis.
    Halder SK; Anumanthan G; Maddula R; Mann J; Chytil A; Gonzalez AL; Washington MK; Moses HL; Beauchamp RD; Datta PK
    Cancer Res; 2006 Jun; 66(12):6156-66. PubMed ID: 16778189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.
    Muñoz NM; Upton M; Rojas A; Washington MK; Lin L; Chytil A; Sozmen EG; Madison BB; Pozzi A; Moon RT; Moses HL; Grady WM
    Cancer Res; 2006 Oct; 66(20):9837-44. PubMed ID: 17047044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
    Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.
    Van Aarsen LA; Leone DR; Ho S; Dolinski BM; McCoon PE; LePage DJ; Kelly R; Heaney G; Rayhorn P; Reid C; Simon KJ; Horan GS; Tao N; Gardner HA; Skelly MM; Gown AM; Thomas GJ; Weinreb PH; Fawell SE; Violette SM
    Cancer Res; 2008 Jan; 68(2):561-70. PubMed ID: 18199553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.